Level C· Early human research exploring benefitsRetrospective StudyPubMed

Micro-Fragmented Adipose Tissue (MFAT) in Orthopedic Regenerative Medicine: A Narrative Review of the Biological Basis and Clinical Evidence.

Yuan C., Goyle AK., Guirguis M., Kaye AD., Grami V., Dave K.

Retrospective Study on Knee Osteoarthritis, Osteoarthritis, Tendon Injury, Hip Osteoarthritis, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Int J Mol Sci (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42511529
DOI
10.3390/ijms27146185

Abstract (original English)

Micro-fragmented adipose tissue (mFAT) is a promising autologous biologic in regenerative medicine because it provides a mechanically processed adipose-derived product that preserves native extracellular matrix architecture and a cellular milieu rich in mesenchymal stem cells, pericytes, growth factors, cytokines, and extracellular vesicles. Mechanistically, mFAT is hypothesized to act largely through paracrine signaling that dampens inflammation, supports vascular stabilization, and promotes cartilage and soft-tissue repair; in vitro data suggest modulation of osteoarthritic synovial macrophage signaling, including reductions in chemokines such as CCL2 and CCL3. Preparation involves liposuction harvest followed by closed, sterile mechanical processing without enzymatic digestion or cell expansion, aligning with "minimal manipulation" concepts relevant to regulatory frameworks. Preclinical animal studies generally demonstrate favorable effects on synovial inflammation and cartilage matrix markers (e.g., glycosaminoglycan content) with limited adverse events. Clinically, the strongest body of evidence is in knee osteoarthritis, where multiple prospective and retrospective studies report improvements in pain and function from months to several years after single injections, though response rates vary and study designs are heterogeneous. Evolving data support potential benefit in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRegenerative MedicineAdipose TissueAnimalsMesenchymal Stem CellsOsteoarthritisOrthopedics

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research